Biphasic insulin analogs: their potential in the management of type 2 diabetes mellitus

Oranskaya A.N.

doi:https://doi.org/

References:

Dedov I.I., Shestakova M.V. Inkretiny: novaya vekha v lechenii sakharnogo diabeta 2-go tipa. Prakticheskoe rukovodstvo dlya vrachei. M: Dipak 2010;92.
American Diabetes Association, Diabetic retinopathy. Diabetes Care 2002;25:Suppl 1:S90-S93.
American Diabetes Association, Diabetic nephropathy. Diabetes Care 2002;25:Suppl 1:S85-S89.
Gaede P., Sund-Andersen H., Parving H.H. et al. Effect of multifactorial intervention on mortality in Type 2 diabetes. N Engl J Med 2008;258:580-591.
Diabetes Control and complication trial research Group/ The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
UK Prospective Diabetes Study (UKPDS) Group/ Intensive blood-glucose control with sulphonilureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS). Lancet 1998;352:837-853.
Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I. Dedova, M.V. Shestakovoi. Izd. 4-e. M 2009.
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2009;32:Suppl 1:S13-S16.
Shim W.S., Kim S.K., Kim H.J. Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol 2006;155:4:615-622.
Turner R.C., Cull C.A., Frigbi V. et al. For the UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012.
Gerich L.E. Arch Int Med 2003;163:1306-1316.
Landgraf R. Diabet Vetab Res Rev 2004;20:Suppl 2:S9-S12.
Owens D.R., Zinman B., Bolli G.B. Lancet 2001;358:739-746.
Gammeltoft S., Hansen B.F., Dideriksen L. et al. Insulin aspart, a novel rapid-acting human insulin analogue. Exp Opin Invest Drugs 1999;8:9:1431-1442.
Kurtzhals P., Schaffer L., Sorensen A. et al. Correlations of receptor binding and metabolic and mitogenic potenticies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005.
Jacobsen L., Bell P., McSorley P. et al. Biphasic insulin aspart and biphasic human insulin in Type 2 diabetes: a comparison. Diabetes 2000;49:Suppl 1:A112.
Riddle M.C. Am J Med 2004;116:Suppl 3A:10S-16S.
Heise T., Heinemann L., Övelmann U.H. et al. Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy 2. Diabetes Care 2009;32:1431-1433.
Garber J., Wahlen J., Wahl T. et al. Attainment of glycaemic goals in type 2 diabetes with once, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006;8:58-66.
Kabadi & Kabadi. Diabetes Res Clin Prac 2006;72:3:265-270.
Raskin et al. Diabetes 2006;55:Suppl 1:131.
Kann P.H., Wascher T. et al. Starting insulin therapy in type 2 diabetes:twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabet 2006;114:9:527-532.
Strojek K., Bebakar Wan M.W., Khutsoane D.T.M. Pesic, Alena Šmahelové, Henrik F. Thomsen, S.Kalra Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs:an open-label, multinational RCT. Curr Med Res Opin 2009;25:12:2887-2894.
et al. Terapiya dvukhfaznym insulinom aspart 30/70 (NovoMiks 30) uluchshaet glikemicheskii kontrol' u patsientov s sakharnym diabetom 2-go tipa: dannye rossiiskoi kogorty patsientov nablyudatel'noi programmy IMPROVE - programmy po izucheniyu bezopasnosti i effektivnosti dvukhfaznogo insulina aspart 30 v rutinnoi klinicheskoi praktike Shestakova M.V., Ballan Akil. Sakharnyi diabet 2010;1:3-10.
Holman R.R., Thorne K.I. et al. 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:17:1716-1730.
Jang H.C., Guler S., Shestakova V. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensifi/cation with a modern premixed insulin help? Result from a subanalysis ofthe PRESENT study. Int J Clin Pract 2008;62:1013-1018.
Liebl A., Prager R., Kaiser M. et al. The PREFER study: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target <7,0%. EASD 2006;Poster 998.
Khutsoane D., Sharma S.K., Almustafa M. et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab 2008;10:212-222.
Lee W.C., Balu S., Cobden D. et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-1725.
Riddle M.C., Schneider J. Beginning insulin treatment of obese patients with evening 30/70 insulin plus glimepiride versus insulin alone. Diabetes Care 1998;21:7:1052-1057.
Boehm B., Home P., Kamp N. et al. Biphasic insulin aspart and biphasic human insulin compared in Type 2 diabetic subjects. Diabetologia 2001;44:Suppl 1:A210.
Boehm B., Home P., Behrend S. et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med 2002;19:5:393-399.
GAO Yan and GUO Xiao-hui Switching from human insulin to biphasic insulin aspart 30 treatment gets more patients with type 2 diabetes to reach target glycosylated hemoglobin <7%: the results from the China cohort of the PRESENT study. Chinese Med J 2010;123:9:1107-1111.
Walid K.H., Fakhoury Hartmut Richter, Torsten E. Christensen Real-Life Dosage and Clinical Efficacy of Biphasic Insulin Preparations in Patients with Type 2 Diabetes/Received: August 24, 2010/Published online: October 11, 2010. Healthcare: Springer 2010.